Dr. Kurtz Discusses Using ctDNA to Detect Lymphoma

David M. Kurtz, MD, PhD
Published: Friday, Aug 03, 2018



David M. Kurtz, MD, PhD, instructor of medicine, Postdoctoral Fellow, Divisions of Oncology & Hematology, Stanford Cancer Center, Stanford University, discusses using circulating tumor DNA (ctDNA) to detect lymphoma.

Kurtz says the in order to detect a patient’s lymphoma using ctDNA, the mutations that drive the lymphoma need to be identified first. A biopsy is taken, and is then sequenced using a next-generation sequencing (NGS) platform. Once the molecular bar code of the patient’s lymphoma is identified, their progress can be tracked over time through their blood plasma, Kurtz says. Through this blood draw, DNA from the plasma can be isolated and sequenced, he explains.

For patients at risk of recurrence, blood plasma samples can be sequenced. According to Kurtz, ctDNA can be used to monitor the disease throughout therapy, including at relapse and at the completion of therapy. Utilizing liquid biopsies to collect ctDNA in conjunction with NGS is a method that is being used across multiple tumor types.
SELECTED
LANGUAGE


David M. Kurtz, MD, PhD, instructor of medicine, Postdoctoral Fellow, Divisions of Oncology & Hematology, Stanford Cancer Center, Stanford University, discusses using circulating tumor DNA (ctDNA) to detect lymphoma.

Kurtz says the in order to detect a patient’s lymphoma using ctDNA, the mutations that drive the lymphoma need to be identified first. A biopsy is taken, and is then sequenced using a next-generation sequencing (NGS) platform. Once the molecular bar code of the patient’s lymphoma is identified, their progress can be tracked over time through their blood plasma, Kurtz says. Through this blood draw, DNA from the plasma can be isolated and sequenced, he explains.

For patients at risk of recurrence, blood plasma samples can be sequenced. According to Kurtz, ctDNA can be used to monitor the disease throughout therapy, including at relapse and at the completion of therapy. Utilizing liquid biopsies to collect ctDNA in conjunction with NGS is a method that is being used across multiple tumor types.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Archived Version of a Live Webcast: Virtual Current Trends™: European Perspectives on the Advancing Role of CAR T-Cell Therapy in Hematologic MalignanciesJun 29, 20192.0
Community Practice Connections™: New Directions in Advanced Cutaneous Squamous Cell Carcinoma: Emerging Evidence of ImmunotherapyAug 13, 20191.5
Publication Bottom Border
Border Publication
x